Western University

Scholarship@Western
Electronic Thesis and Dissertation Repository
12-13-2013 12:00 AM

Non-Neuronal Acetylcholine Secretion by Neonatal Murine
Cardiomyocytes
William Fields, The University of Western Ontario
Supervisor: Marco Prado, The University of Western Ontario
A thesis submitted in partial fulfillment of the requirements for the Master of Science degree in
Neuroscience
© William Fields 2013

Follow this and additional works at: https://ir.lib.uwo.ca/etd

Recommended Citation
Fields, William, "Non-Neuronal Acetylcholine Secretion by Neonatal Murine Cardiomyocytes" (2013).
Electronic Thesis and Dissertation Repository. 1782.
https://ir.lib.uwo.ca/etd/1782

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

NON –NEURONAL ACETYLCHOLINE SECRETION BY NEONATAL MURINE
CARDIOMYOCYTES
(Thesis format: Monograph)

by

William C. Fields

Graduate Program in Neuroscience

A thesis submitted in partial fulfillment
of the requirements for the degree of
Master of Science

The School of Graduate and Postdoctoral Studies
The University of Western Ontario
London, Ontario, Canada

© William C. Fields 2013

Abstract
Recent studies have shown that murine cardiomyocytes possess a functional intrinsic
cholinergic system that can synthesize and release acetylcholine (ACh). The way by
which ACh release is regulated however, is not fully understood. Classically, ACh
released from neuronal sources is regulated by the vesicular ACh transporter (VAChT).
We tested the hypothesis that ACh released from neonatal murine cardiomyocytes is
regulated via the VAChT by pharmacologically inhibiting or genetically removing this
transporter selectively from cardiomyocytes. Pharmacological inhibition of the VAChT
using vesamicol (VES) revealed a significant reduction in ACh release from cultured
cardiomyocytes. Cardiomyocytes from genetically-modified mice where the VAChT was
selectively removed revealed similar reductions in ACh release. Similar to its role within
nerve terminals, these data suggest that the VAChT serves an essential role in regulating
ACh release from cardiomyocytes. These experiments suggest that non-neuronal ACh
released from cardiomyocytes may act to amplify the effects of neuronally released ACh.
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Chapter 1

1

Introduction

1.1 Cholinergic Neurotransmission
Neurotransmitters are those chemicals endogenous to an organism which act by
transmitting impulses across synaptic clefts located either between pre- and post-synaptic
neurons or pre-synaptic neurons and target cells (Purves D, 2001). Acetylcholine (ACh),
one of the most widely studied neurotransmitters to date, was discovered in 1926 by the
German physiologist, Otto Loewi. The discovery came following the dissection of two
beating frog hearts; one with an intact vagus nerve and the other lacking it. Loewi then
placed both hearts into a saline solution, stimulated the vagus nerve of the intact heart,
and the result was a decrease in heart rate (HR). Loewi then took a portion of the fluid
from the stimulated heart and applied it to the second heart where he found a similar
reduction in HR. This led Loewi to conclude that HR was being regulated by a chemical
released from the vagus nerve (Purves D, 2001). The molecule that would eventually be
given the name ACh, serves as a neurotransmitter for both the central (CNS) and
peripheral nervous systems (PNS).
In order for ACh to function as a neurotransmitter, it must be synthesized, packaged into
vesicles, released into the synaptic cleft, and finally degraded by an acetylcholinesterase
enzyme (AChE). These processes are tightly regulated through three main cholinergic
proteins including the high affinity choline transporter (CHT1), the choline
acetyltransferase (ChAT) enzyme, and the vesicular acetylcholine transporter (VAChT).
Choline, a water soluble essential nutrient required for sustaining life, serves a role in
brain development, cellular membrane structure, and the modulation of several cell
signaling processes (Zeisel & Blusztajn, 1994). The uptake of choline from extracellular
sources, for the purposes of cholinergic signaling, is under the regulation of the high
affinity choline transporter, CHT1 (Collier & Katz, 1974; R. Birks, 1961). This protein is
a 63 kDa protein which belongs to the Na+-dependent glucose transporter family, SLC5
(SLC5A7) (Apparsundaram, Ferguson, George, & Blakely, 2000; Okuda et al., 2000). As
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the name implies, CHT1 is a membrane embedded protein that exhibits high affinity for
choline molecules present within extracellular spaces (Brandon et al., 2004; Collier &
Katz, 1974; R. Birks, 1961). The high affinity choline transporter localizes mainly at the
membrane of synaptic vesicles, but has also been found, albeit at lower levels, at the
membrane of pre-synaptic nerve endings (Ferguson et al., 2003; Ribeiro et al., 2003). The
high affinity choline transporter has often been described as the rate-limiting step in the
synthesis of ACh considering that the specific inhibition of CHT1 by hemicholinium-3
(HEM) results in severe deficits in cholinergic function (R. Birks, 1961; Ribeiro et al.,
2003). However, under circumstances in which there is a period of prolonged neuronal
stimulation, the synthesis and release of ACh is sustained as long as CHT1 is functioning
properly and as long as there is sufficient choline available for uptake (Ribeiro et al.,
2006). Considering CHT1 localizes predominately at the membrane of synaptic vesicles,
prolonged neuronal stimulation not only increases synaptic vesicle exocytosis, but it
increases the amount of CHT1 present at the plasma membrane following exocytosis.
These conditions facilitate an increase in choline re-uptake by the pre-synaptic neuron
which mediates increased ACh synthesis and provides the foundation required to sustain
prolonged neuronal stimulation (Ribeiro et al., 2006).
Choline acetyltransferase, an enzyme often attributed as being the phenotypical marker of
cholinergic neurons, is a ~69 KD (Dobransky & Rylett, 2003), monomeric, globular
protein (Oda, 1999) responsible for synthesizing ACh from the precursors, choline and
acetyl-CoA (Dobransky & Rylett, 2003). Acetyl-CoA, a biologically important molecule
used in several biochemical reactions, is obtained through three main endogenous
reactions. These reactions include glycolysis, the degradation of amino acids, and the
oxidation of fatty acids (Oda, 1999). Although ChAT is located all throughout
cholinergic neurons, its highest concentration exists within the nerve terminals (Oda,
1999). Choline acetyltransferase is initially produced within the cell body of cholinergic
neurons before being transported to the nerve terminal through axoplasmic transport
(Dziegielewska et al., 1976; Frizell, Hasselgren, & Sjostrand, 1970). Synthesis of ACh by
ChAT commences in the cytoplasm of nerve terminals (Govindasamy et al., 2004; Oda,
1999; Parsons, 2000; M. A. Prado et al., 2002; V. F. Prado, Roy, Kolisnyk, Gros, &
Prado, 2013). Synthesis occurs through a single step reaction in which an acetyl group

3

from acetyl-CoA is transferred to a single molecule of choline (Govindasamy et al., 2004;
Oda, 1999; Yamada, Imajoh-Ohmi, & Haga, 2012). It has also been shown that the open
reading frame of the VAChT, another important protein used in cholinergic signaling, lies
within the first intron of the ChAT gene (Alfonso, Grundahl, McManus, Asbury, & Rand,
1994; Bejanin, Cervini, Mallet, & Berrard, 1994). This may be of particular importance
as it could suggest that the expression of ChAT and the VAChT are coregulated within
cholinergic neurons.
The VAChT is a ~75 kDA protein (Alfonso, Grundahl, Duerr, Han, & Rand, 1993;
Roghani et al., 1994; Varoqui & Erickson, 1996) responsible for loading ACh
synthesized by ChAT into acidic secretory vesicles (Parsons, Prior, & Marshall, 1993;
Usdin, Eiden, Bonner, & Erickson, 1995). The VAChT, a member of the solute carrier
family, SLC18, is a protein found in both neuronal cell bodies, as well as the nerve
terminals of cells containing the ChAT protein (Roghani, Shirzadi, Butcher, & Edwards,
1998; Schafer, Eiden, & Weihe, 1998). The VAChT consists of 12 transmembrane
spanning domains which orient themselves into two main bundles such that the aminoterminus and carboxyl-terminus are both directed towards the cytosolic side of the cell
(V. F. Prado et al., 2013). The two main bundles undergo a back and forth-like motion
such that the substrate-binding site is exposed to either the cytoplasm of the cell or the
interior of the synaptic vesicle (Nguyen, Cox, & Parsons, 1998). This motion allows ACh
to be packaged into acidic vesicles through the exchange of two luminal protons per
cytoplasmic molecule of ACh (Nguyen et al., 1998).
The VAChT mediated storage of ACh can be pharmacologically inhibited through the
use of vesamicol [(−)-trans-2-(4-phenylpiperidino) cyclohexanol] (VES) (V. F. Prado et
al., 2013; Prior, Marshall, & Parsons, 1992). Vesamicol is a tertiary amine that can
traverse the cell membrane and bind to the VAChT such that it inhibits the transport of
ACh (Nguyen et al., 1998; Parsons et al., 1993). Inhibition by VES has been shown to be
non-competitive in nature indicating that its inhibitory actions take place at a site external
to the ACh binding site (Bahr, Clarkson, Rogers, Noremberg, & Parsons, 1992).
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1.2 Nicotinic and Muscarinic ACh Receptors
Nicotinic ACh receptors (nAChRs), a class of integral membrane proteins, are receptors
which serve as ligand gated ion channels within cholinergic neurotransmission (Chesher
& James, 1966; Kalamida et al., 2007). Nicotinic ACh receptors are composed of 5
transmembrane subunits organized around a central pore and can vary in function
depending on the polypeptide subunits that are present (α1-10, β1-4, γ, δ, and ε)
(Lindstrom, 1997). Although all nAChRs are composed of 5 transmembrane subunits
organized around a central pore, these receptors can be further divided into neuronal and
muscular subtypes (Marshall, 1981). Neuronal subtypes are those receptors that associate
with the CNS, the PNS, and non-neuronal ACh sources (Kalamida et al., 2007). In
contrast, muscular subtypes, as the name implies, are those receptors that associate with
the neuromuscular junction and act to mediate muscular contraction (Kalamida et al.,
2007). Although nAChRs serve an important role within cholinergic neurotransmission,
particular focus will be placed on the role muscarinic acetylcholine receptors (mAChRs)
serve in such transmission.
Muscarinic acetylcholine receptors, a class of G-protein coupled receptors (GPCRs), are
membrane embedded proteins that are present within various cells types, including
neurons, and are responsible for mediating several diverse functions within an organism
(Ashkenazi, Peralta, Winslow, Ramachandran, & Capon, 1988). Named as such because
of their increased sensitivity to muscarine, five different mAChR subtypes have been
identified (M1-M5) (Bonner, Young, Brann, & Buckley, 1988; Hulme, Birdsall, &
Buckley, 1990; Kubo et al., 1986; Liao et al., 1989). All muscarinic receptor subtypes are
composed of seven transmembrane spanning domains with a carboxyl-terminus directed
intracellularly and an amino-terminus directed extracellularly (Dhein, van Koppen, &
Brodde, 2001). The ligand binding site of these receptors are situated within the outer
half of the membrane embedded portion of the receptor protein (Dhein et al., 2001).
Ligand binding and subsequent activation of the various receptor subtypes can produce
differing responses depending on the G-protein the receptor subtype is coupled to (Dhein
et al., 2001). Odd numbered muscarinic receptor subtypes (M1, M3, and M5) for
instance, are coupled to Gq/11 G-proteins, which when activated, results in phospholipase
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C (PLC) stimulation (Dhein et al., 2001; Ishii & Kurachi, 2006). Activation of PLC
initiates a cascade of events beginning with the hydrolysis of Phosphatidylinositol 4,5bisphosphate (PIP2) to its constituents, diacyl glycerol (DAG) and inositol triphosphate
(IP3) (Dhein et al., 2001; Ishii & Kurachi, 2006). Following PIP2 hydrolysis, DAG acts as
a second messenger to activate Protein Kinase C, while IP3 acts to increase intracellular
calcium levels (Dhein et al., 2001; Ishii & Kurachi, 2006). In contrast, even numbered
receptor subtypes (M2 and M4) are coupled to Gi/o G-proteins, which when activated,
serve to inhibit adenylyl cyclase activity (Nathanson, 1987). Consequently there is
decreased production of cyclic adenosine monophosphate (cAMP) and a subsequent
decrease in Protein Kinase A (PKA) activity (Dhein et al., 2001; Ishii & Kurachi, 2006).
Gi/o G-proteins also mediate the activation of G protein-gated potassium channels
resulting in the hyperpolarization of excitable cells (Kim et al., 1989; Logothetis,
Kurachi, Galper, Neer, & Clapham, 1987; Yatani et al., 1988).
There are five different mAChR subtypes which exist and a particular tissue is capable of
expressing multiple receptor subtypes at any given time (Brodde & Michel, 1999). For
instance, the heart expresses, albeit at different levels, both M2 and M3 receptor subtypes
(Sharma, Colecraft, Rubin, & Sheu, 1997; Z. Wang, Shi, & Wang, 2004; Yang, Yeh,
Sung, Chen, & Wang, 1992). The M2 receptor subtype, denoted as the muscarinic type-2
ACh receptor (mAChR-2), is the predominant receptor subtype present within the heart.
The M3 receptor subtype seems to serve only a minor role as it has been described as
carrying-out functions associated mainly with the coronary circulation (Dhein et al.,
2001). For this reason, the mAChR-2 and the effects it exerts on the heart are of
particular importance.
Muscarinic type-2 ACh receptors can be activated by a plethora of different agonists
including ACh and carbachol (Carb) (Brodde & Michel, 1999). When these receptors are
activated at the heart, a reduction in heart rate (chronotropy), force of contraction
(inotropy), and conduction velocity (dromotropy) ensues (Brodde & Michel, 1999). More
specifically, activation of these receptors at the sinoatrial node (SA) elicits an increase in
outward potassium conductance, while decreasing the inward conductance of calcium
and sodium ions. Consequently, SA nodal cells hyperpolarize and reduce the rate at
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which these cells spontaneously depolarize. The net result is a reduction in the rate of
action potential (AP) firing from these cells (Giessler, Dhein, Ponicke, & Brodde, 1999).
Furthermore, activation of mAChRs-2 produces a shortened AP within the atria, as well
as a decrease in the velocity at which the AP propagates through the atrioventricular
(AV) node (Giessler et al., 1999). Lastly, activation of these receptors can elicit a slight
reduction in the force at which the ventricles contract, as long as the cAMP pathway has
been stimulated beforehand in a phenomenon termed accentuated antagonism (Brodde &
Michel, 1999; Giessler et al., 1999; Levy, 1984). The effects produced by mAChR-2
activation can be competitively inhibited through the use of atropine (ATR), a nonspecific muscarinic receptor antagonist (Bhattacharjee, Pomponio, Evans, Pervitsky, &
Gordon, 2013).

1.3 The Role of Acetylcholinesterase in Cholinergic
Neurotransmission
Acetylcholinesterase, a hydrolase enzyme located within the synaptic cleft of cholinergic
neurons, serves to hydrolyze ACh into acetic acid and choline (Sussman et al., 1991;
Pohanka, 2011). The enzymatic breakdown of ACh is a crucial process required by
organisms to maintain cholinergic neurotransmission. The active site of these enzymes is
composed of two subsites including the anionic subsite, as well as the esteratic subsite
(Sussman et al., 1991). The anionic subsite is responsible for interacting with the
quarentary amine of the ACh molecule to ensure the molecule is in the correct
orientation for subsequent hydrolysis (Sussman et al., 1991).

The esteratic subsite

however, is the portion of the active site where the ester bond joining acetic acid and
choline together is broken through hydrolysis. This site contains three essential amino
acids including serine, histidine, and glutamate and is often referred to as the catalytic
triad (Silman & Sussman, 2008; Sussman et al., 1991). The hydrolysis of ACh by
AChEs to acetic acid and choline can be slowed however, through the use of
acetylcholinesterase inhibitors (AChEIs). The method by which AChEIs exerts their
inhibitory effects depends on the type of AChEI present. The two AChEIs of particular
importance, pyridostigmine (PYR) and neostigmine (NEO), act as reversible inhibitors
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to the AChE enzyme (Androne, Hryniewicz, Goldsmith, Arwady, & Katz, 2003; Miller,
Van Nyhuis, Eger, Vitez, & Way, 1974). Although both inhibitors act in a similar
fashion, PYR, compared to NEO, requires more time to reach peak onset, but its actions
as a cholinesterase inhibitor are of a longer duration (Miller et al., 1974; Smith, Mead, &
Unna, 1957).

1.4 An Overview of Cholinergic Neurotransmission
After discussing the roles of CHT1, ChAT, the VAChT, nAChRs, mAChRs, AChEs and
AChEIs in cholinergic neurotransmission, a broader picture depicting how cholinergic
neurotransmission proceeds can be put forth. The initial stage of cholinergic
neurotransmission begins in the cytoplasm of the nerve terminal where ACh is
synthesized through the enzymatic actions of ChAT (Dobransky & Rylett, 2003).
Following its synthesis, ACh is then packaged into acidic vesicles through the actions of
the VAChT (V. F. Prado et al., 2013). Once ACh is packaged into acidic vesicles, ACh is
ready for release into the synaptic cleft where it can bind to nAChRs or mAChRs to elicit
a given response. In order for the vesicular contents to be released into the synaptic cleft
in a synchronous fashion however, an AP must first be generated at the cell body of the
neuron. Following its generation, the AP then propagates to the nerve terminal (Hall,
2010; Katz, 1969). Depolarization of the nerve terminal results in the opening of voltagegated calcium channels causing an influx of extracellular calcium into the pre-synaptic
neuron (Katz, 1969). Calcium influx in turn causes ACh-containing vesicles to fuse with
the membrane of the pre-synaptic neuron at which point ACh is released into the synaptic
cleft through a process known as exocytosis (Hall, 2010; Katz, 1969). Depending on the
location of the synapse, ACh released into the synaptic cleft is free to act on either
nAChRs (Guo, Liu, Sorenson, & Chiappinelli, 2005) or mAChRs (Abramochkin et al.,
2010). These effects are short lived however, because of the actions of the AChE
enzyme. These enzymes work at an extremely rapid rate to hydrolyze ACh to acetic acid
and choline (Minic, Molgo, Karlsson, & Krejci, 2002; Soreq & Seidman, 2001).
Following the enzymatic breakdown of ACh, choline can be recycled back into the nerve
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terminal through the actions of CHT1 (Collier & Katz, 1974; R. Birks, 1961) where it can
then be utilized for the synthesis of additional molecules of ACh.

1.5 Neural and Humoral Control of the Heart
The pumping and subsequent delivery of blood through the use of a connected circulatory
system is critical for the delivery of oxygen and essential nutrients to each and every cell
of the body (Vadakkumpadan et al., 2010). The delivery of blood can be altered however,
in order to meet the metabolic demands of the body by altering vascular resistance or by
altering the heart’s inotropic and chronotropic responses. The frequency and strength at
which these contractions occur is regulated by both a system intrinsic to the heart, as well
as system extrinsic to the heart (Randall, Evans, Billman, Ordway, & Knapp, 1981).
Intrinsic control of the heart refers to the hearts’ ability to regulate its inotropic and
chronotropic responses in the absence of external neural control. Intrinsic control of the
heart is regulated by a specialized group of cells often referred to as pacemaker cells
(Tessadori et al., 2012). Pacemaker cells are responsible for initiating and distributing
electrical impulses in a coordinated fashion throughout the heart (Tessadori et al., 2012).
In other words, the heart can be described as having automaticity or self-excitability,
since cardiomyocytes are capable of initiating spontaneous electrical impulses in the
absence of external neural control. The spontaneous depolarization of pacemaker cells is
the result of changes in membrane conductance to sodium, potassium, and calcium ions
(Jones Bernardes Graceli, 2012). Once pacemaker cells reach threshold, an impulse is
generated where it then propagates through internodal pathways (Kafer, 1991).
Propagation through these pathways allows for atrial depolarization followed by atrial
contraction (Kafer, 1991). During atrial contraction, the impulse propagates to a
specialized group of cells located within the atrial septum known as the AV node (Chi et
al., 2008). While the AV node depolarizes, repolarization of both the SA node and the
internodal pathways commences (Nada et al., 2013). Following a slight delay at the AV
node to allow for ventricular filling (Chi et al., 2008; Marger et al., 2011), the impulse
then propagates through the bundle of His, as well as the left and right bundle branches,
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before finally reaching the Purkinje fibers (Chi et al., 2008). Depolarization of the
Purkinje fibers causes ventricular contraction from the apex of the heart to the base of the
heart resulting in the expulsion of blood from the ventricles (Chi et al., 2008). During
ventricular contraction, the atria rest and undergo repolarization (Nada et al., 2013).
Following ventricular contraction, the AV node, the bundle of His, and the Purkinje
fibers repolarize while the ventricles relax (Nada et al., 2013). In some cases however,
the pacemaker cells of the SA node lose their automaticity. Considering that other cells in
the heart are self-excitable, the role of the pacemaker can be assumed by these cells,
albeit at a slower rate. The first area of the heart to embrace this role once pacemaker
cells lose their automaticity, are the cells of the AV node (Marger et al., 2011). If for
some reason the cells of the AV node also lose their automaticity, the role can be
assumed by the bundle of His and the Purkinje fibers (Chay & Lee, 1984). Under normal
circumstances, the self-excitability of the AV node, the bundle of His, and the Purkinje
fibers are much slower than the pacemaker cells of the SA node (Tessadori et al., 2012).
Consequently, APs generated by the SA node are able to propagate through the
conduction system and excite the AV node, the bundle branches, and the Purkinje fibers
before these areas have a chance to generate their own spontaneous AP (Tessadori et al.,
2012). For this reason, the spontaneous generation of APs by the SA node tends to be
approximately 100 times per minute but because of extrinsic regulation, this rate is
modified to approximately 70 times per minute.
Extrinsic control of the heart refers to the organism’s ability to externally regulate heart
function through the release of neurotransmitters [ie. Norepinephrine (NE) and ACh]
from the autonomic nervous system (ANS) (Vaseghi & Shivkumar, 2008). The ANS, a
division of the PNS, is responsible for controlling involuntary and visceral functions
(Chen, Wasmund, & Hamdan, 2006). At the heart specifically, the ANS is responsible for
regulating the hearts’ chronotropic, inotropic, and dromotropic effects through the
coordinated interplay of its two subdivisions (Vaseghi & Shivkumar, 2008) which
include the sympathetic (SNS) and parasympathetic nervous systems (PSNS).
The SNS is a division of the PNS often referred to as the “fight-or-flight” system and its
actions predominate over the PSNS during time of physiological stress (Floras, 2009).
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With reference to the heart, adrenergic nerves of the SNS originate in the thoracic and
lumbar regions of the spine before eventually innervating the atria, the ventricles, and the
ventricular conducting system (Camici, 2002; Chen et al., 2006; Ieda & Fukuda, 2009;
Mitchell, 1953). During times of physiological stress, an increase in SNS activity causes
an increase in NE secretion from adrenergic fibers. Consequently, there is an increased
concentration of circulating NE which can be utilized for the activation of β-adrenergic
receptors (Camici, 2002; Parati & Esler, 2012). β-adrenergic receptors are a class of
GPCRs that are activated by catecholamines including epinephrine and NE (Ablad et al.,
1974). Activation of these receptors increases the level of activity in the c-AMPdependent pathway (Bristow, Hershberger, Port, Minobe, & Rasmussen, 1989). In short,
activation of adenylyl cyclase by the Gs alpha subunit of the G-protein complex increases
cAMP production and ultimately causes an increase in PKA activity (Bristow et al.,
1989). Activation of PKA leads to several downstream effects at the heart including those
effects aforementioned (Vaseghi & Shivkumar, 2008).
The PSNS however, is a division of the PNS often referred to as the “rest-and-digest”
system and its actions predominate over the SNS during times of rest and relaxation
(Stewart, Huang, & Fisher, 2012). In contrast to the SNS, the vagus nerve of the PSNS
originates in the brainstem and innervates the SA/AV nodes, the atria, the ventricular
conducting system, but only sparsely innervates the ventricles (Blotnick, Hamra-Amitai,
Wald, Brenner, & Anglister, 2012; Chen et al., 2006; Hildreth, Anderson, & Henderson,
2009; Mitchell, 1953). Activation of the PSNS elicits an increase in ACh release from
cholinergic neurons. Consequently, there is an increase in mAChR-2 activation resulting
in an increased cholinergic tone (Abramochkin et al., 2010; Minic et al., 2002; Wessler &
Kirkpatrick, 2008). Like β-adrenergic receptors, mAChRs-2, as previously described, are
a class of GPCRs that regulate chronotropy, inotropy, and dromotropy (Brodde &
Michel, 1999; Giessler et al., 1999). In contrast to β-adrenergic receptors however,
mAChRs-2 work to decrease those effects previously mentioned (Brodde & Michel,
1999; Giessler et al., 1999) It should also be noted that chemical stimuli present within
the circulation (ie. tissue metabolites, CO2, O2, and adenosine) can effect cardiac function
by altering the degree of neural outflow from the SNS and the PSNS (Thomas, 2011).
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1.6 The importance of ACh in Maintaining Cardiovascular
Homeostasis
Cholinergic neurotransmission plays an important role in maintaining cardiovascular
health considering that alterations in cholinergic protein expression and/or a withdrawal
of PSNS activity elicits several cardiovascular deficits. Although decreased cholinergic
tone results in deficits including left ventricular dysfunction (Lara et al., 2010), decreased
HR variability (Serra, Costa, Teixeira De Castro, Xavier, & Nobrega, 2009), and cardiac
remodeling (Li et al., 2004), normal cardiovascular function can be restored, or at least
improved, following AChE inhibition or treatment with chronic vagal stimulation (Lara
et al., 2010; Li et al., 2004).
Both animal studies, as well as human studies, have shown that AChE inhibition can be
beneficial in restoring normal cardiovascular function in models with cardiac
dysfunction. For instance, those mice experiencing a reduction in the level of functioning
VAChT protein (VAChT KDHOM) to approximately 30% of normal levels, presented with
decreased levels of peak calcium, as well as a decrease in the rate of calcium decay (Lara
et al., 2010). Inefficient calcium handling by cardiomyocytes has been shown to have a
significant influence on the normal physiology of these cells (Bers, 2002, 2006).
Furthermore, altered

calcium handling is considered to be a key biological marker for

chronic heart failure (CHF) and several cardiac pathologies (Vahl, Bonz, Timek, & Hagl,
1994). In addition to altered calcium handling, VAChT KDHOM mice exhibited significant
reductions in left ventricular fractional shortening, indicative of left ventricular
dysfunction (Lara et al., 2010). Interestingly, peak calcium and calcium decay, as well as
left ventricular fractional shortening, were all restored to WT levels following AChE
inhibition by PYR (Lara et al., 2010). These results suggest that cholinergic
neurotransmission is critical for maintaining normal cardiovascular function, since a
decrease in the level of functioning VAChT protein produced a phenotype consistent with
heart dysfunction which was restored following AChE inhibition. The beneficial effects
of AChE inhibition on cardiovascular function were also shown in a study by Okazaki et
al., 2010 in which rats with CHF were treated with the AChEI donepezil. When these rats
were subjected to AChE inhibition using donepezil, their left ventricular end diastolic
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pressure (LVEDP) and heart weights were significantly reduced compared to controls.
Similarly, neurohumoral factors associated with the SNS, including NE and epinephrine,
were significantly reduced following treatment with donepezil. (Okazaki, Zheng, Li, &
Sugimachi, 2010). Interestingly, the beneficial effects of AChE inhibition have been
described in clinical trials as well (Serra et al., 2009). One such trial showed that AChE
inhibition by PYR in patients with CHF elicited an increase resting HR variability and
decreased the incidence of ventricular arrhythmias, while also improving HR recovery
following exercise (Serra et al., 2009). Furthermore, a recent study examining the
correlation between AChE inhibition and myocardial infarctions (MI) revealed that the
use of AChEI was correlated to a reduction in the risk of MI and mortality rate
(Nordstrom, Religa, Wimo, Winblad, & Eriksdotter, 2013). Interestingly, Nordstrom et
al., 2013 reported that this correlation was even stronger when increasing doses of the
AChEI were utilized.
Similar to the beneficial effects of AChE inhibition on cardiovascular function, studies
involving chronic vagal stimulation have also shown to be quite beneficial. A study
performed by Li et al., 2004 showed that when rats with CHF underwent chronic vagal
stimulation, there was a significant decrease in both hemodynamic changes, as well as
heart weights, compared to control rats. Li et al., 2004 also reported that when rats with
CHF underwent chronic vagal stimulation, there was a marked improvement in long-term
survival rate by preventing the progression of pumping failure and cardiac remodeling. A
study performed by Sabbah and Cohen in 2005 in which canines were induced with a MI
through the use of an intracoronary embolism, revealed that there was a significant
improvement in left ventricular hemodynamics following chronic vagal stimulation
compared to control canines. Sabbah and Cohen (2005) also showed that concomitant use
of a β-blocker, along with chronic vagal stimulation, resulted in a significant increase in
left ventricular ejection fraction (LVEF), as well as a significant decrease in left
ventricular end systolic volume (LVESV) compared to canines treated simply with a βblocker (Sabbah HN & Cohen U, 2005). It has also been reported that there was a
significant increase in proinflammatory cytokines in models of CHF, including tumor
necrosis factor alpha and interleukin 6, both of which are highly correlated with
morbidity and mortality (H. Wang et al., 2003). Interestingly, there is a reduction in those

13

proinflammatory cytokines aforementioned following chronic vagal stimulation (H.
Wang et al., 2003). Clinical trials performed on individuals whose LVEF was less than
35% also reaped the beneficial effects of chronic vagal stimulation. In these patients,
electrical pulsers were implanted in such a fashion to ensure that vagal stimulation
occurred at specific intervals based on the patient’s prior health. Data acquired 3 months
following implantation showed that chronic vagal stimulation significantly reduced basal
HR and significantly improved the distance in which these patients could travel during a
six minute walk test (De Ferrari, Sanzo, & Schwartz, 2009). Furthermore, data acquired
one year post implantation revealed a significant increase in the patient’s LVEF (De
Ferrari et al., 2009). Not only did these data show the beneficial effect of chronic vagal
stimulation on cardiovascular function, but patient interviews following this treatment
also revealed that there was a general improvement in their quality of life (De Ferrari et
al., 2009).
Although those studies mentioned above show how AChE inhibition and chronic vagal
stimulation are beneficial in restoring or maintaining normal cardiovascular function,
other studies have shown more generally just how important the PSNS and its associated
proteins are in maintaining cardiovascular homeostasis. For instance, it has been shown
that mAChR-2 knockout mice display impaired ventricular function, as well as an
increased susceptibility to cardiac stress and cardiomyocyte remodeling (LaCroix,
Freeling, Giles, Wess, & Li, 2008; Lara et al., 2010). Furthermore, a study performed by
Nolan et al., 1992 revealed a significant correlation between the degree of
parasympathetic impairment and the severity of left ventricular dysfunction. Finally, it
has been shown in both animal models and humans with CHF, that there is cholinergic
transdifferentiation of the cardiac SNS. Transdifferentiation of the cardiac SNS is the
result of several factors being secreted from failing cardiomyocytes which switch neurons
normally sympathetic in nature, to cholinergic neurons by altering the neurotransmitter
that is released (Kanazawa et al., 2010). Inhibiting this transdifferentiation resulted in
increased mortality within these mice.
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1.7 The Emergence of Non-Neuronal Cholinergic Systems
If one considers that essentially all living cells, including epithelial cells, endothelial
cells, immune cells, etc., have the ability to synthesize ACh, then the idea of ACh acting
solely as a neurotransmitter must be revised (Wessler & Kirkpatrick, 2008). Evidence
supporting the synthesis of ACh by multiple non-neuronal cell types has been confirmed
through several experiments. Such experiments have revealed ChAT immunoreactivity
and ChAT enzymatic activity, as well as the intracellular presence of ACh in nonneuronal cells (Wessler & Kirkpatrick, 2008). Although ACh has been found in several
non-neuronal sources, an argument suggesting that its presence in these sources is due to
neuronal contamination could be made. However, based on several findings from the last
few decades, the possibility of non-neuronal contamination by neuronal sources can be
ruled out. Two such studies were performed on isolated epithelial cells, as well as
immune cells, where the presence of both ChAT mRNA and ChAT protein were found
intracellularly (Grando et al., 1993; Klapproth et al., 1997). Several other studies have
provided evidence supporting the work completed by Grando et al., 1993 and Klapproth
et al., 1997, where they were able to detect ChAT within non-neuronal cells by using
antibodies targeted against it (Wessler & Kirkpatrick, 2008). Perhaps the most
convincing finding comes from the human placenta and its ability to synthesize, store,
and release ACh in the absence of cholinergic innervation (Wessler et al., 2001). Finally,
studies performed by Kao et al., 1976 and Schlereth et al., 2006 have provided evidence
refuting the argument that ACh present within non-neuronal sources was due to neuronal
contamination. In these two studies, botulism toxin was used to inhibit the exocytotic
release of ACh. When dermal microdialysis was utilized following this treatment, it was
determined in vivo, that human skin cells could secrete non-neuronal ACh (Kao,
Drachman, & Price, 1976; Schlereth et al., 2006). Considering the studies
aforementioned, it becomes apparent that non-neuronal cells possess the ability to
synthesize, store, and release ACh.
Although several functions have been attributed to the non-neuronal release of ACh,
perhaps its role in signal transduction is most important (Wessler & Kirkpatrick, 2008).
As a signal transducing molecule, ACh can act through autocrine and paracrine
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mechanisms to regulate basic cellular functions including cell proliferation, cell
differentiation, and cell-cell contact (Wessler, Herschel, Bittinger, & Kirkpatrick, 2007).
Its role in signal transduction has been revealed in several physiological systems, as well
as pathological conditions, including the placenta (Wessler et al., 2007), the pancreas
(Rodriguez-Diaz et al., 2011), the colon (Yajima, Inoue, Matsumoto, & Yajima, 2011),
lymphocytes (Kawashima & Fujii, 2004), and a variety of different cancers (Wessler &
Kirkpatrick, 2008; Yajima et al., 2011). In the placenta for example, non-neuronal ACh
acts through nAChRs to regulate blood flow and fluid volume in placental vessels, the
uptake of nutrients, and vascularization during placental development (Wessler et al.,
2007). In the pancreas, non-neuronal ACh released by the alpha cells serves as a feedforwarding signal to sensitize the beta cell response to increasing glucose concentrations,
thereby limiting glucose fluctuations within the plasma (Rodriguez-Diaz et al., 2011).
Furthermore, it has been suggested that the intracellular signaling pathways activated by
ACh may promote long-term survival of beta cells through the use of tropic factors
(Rodriguez-Diaz et al., 2011). In the colon, non-neuronal ACh released from colonocytes,
in conjunction with propionate stimulation, serves as a signaling molecule which can act
in a paracrine fashion through muscarinic receptors to regulate chloride secretion (Yajima
et al., 2011). Chloride secretion in the colon is critical to maintaining normal
physiological function as it plays an essential role in regulating mucosal hydration
(Barrett & Keely, 2000). Finally, studies have revealed the synthesis and release of nonneuronal ACh from tumor cells (Song & Spindel, 2008) and lymphocytes (Kawashima &
Fujii, 2004). Tumor cells, such as those found in lung cancers, have revealed that nonneuronal ACh can act in an autocrine or paracrine fashion to stimulate an increase in
tumor cell growth (Song & Spindel, 2008).

Furthermore, it has been shown that

lymphocytes possess an intrinsic non-neuronal cholinergic system as well (Kawashima &
Fujii, 2004). This system has been shown to serve a role in the cholinergic antiinflammatory pathway by regulating immune function as well as local circulation
(Kawashima & Fujii, 2004; Rosas-Ballina et al., 2011)
Interestingly, recent evidence has revealed that the machinery required for the synthesis
and release of ACh is present within cardiomyocytes themselves (Kakinuma, Akiyama,
& Sato, 2009; Rana et al., 2010; Rocha-Resende et al., 2012). Results from these studies
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have shown that the VAChT localizes in the perinuclear region of cardiomyocytes
(Kakinuma et al., 2009; Rana et al., 2010; Rocha-Resende et al., 2012). Similarly, these
studies have shown that ChAT localizes in and around the nucleus, while CHT1 localizes
at the plasma membrane (Kakinuma et al., 2009; Rana et al., 2010; Rocha-Resende et al.,
2012). The presence of the VAChT, ChAT, and CHT1 and their locations throughout
cardiomyocytes puts them in an ideal position to synthesize and secrete ACh. Since it
has been shown previously that cardiomyocytes can in fact secrete ACh (Kakinuma et al.,
2009; Rocha-Resende et al., 2012), it would be interesting to determine the mechanism
by which cardiomyocytes are regulating this release.

1.8 Direction, Aims, and Hypothesis
As mentioned previously, ACh release at the heart is essential in maintaining
cardiovascular function. More specifically, AChE inhibition, as well as chronic vagal
stimulation, has been shown to improve left ventricular function in models of CHF.
These findings are perplexing as parasympathetic innervation is found mainly at the
SA/AV node and only sparsely at the ventricles. Based on the recent emergence of a nonneuronal cholinergic system within cardiomyocytes, (Kakinuma et al., 2009; Rana et al.,
2010; Rocha-Resende et al., 2012) along with their ability to secrete ACh (Kakinuma et
al., 2009; Rocha-Resende et al., 2012; A. Roy, Fields, W.C., Rocha-Resende, C.,
Resende, R.R., Guatimosim, S.,Prado, V.F.,Gros, R., and Prado, M.A. , 2013), these
results taken together could suggest that this system serves a physiologically important
role in the heart. To better understand how a non-neuronal cholinergic system functions
in the heart, the aim of this project was to determine the mechanism regulating ACh
release from cardiomyocytes. Considering ACh released from cholinergic neurons is
regulated by the VAChT (de Castro et al., 2009; Lara et al., 2010), it is thought that ACh
released from cardiomyocytes may be regulated in a similar fashion. Therefore, the
hypothesis of this study is that ACh secreted from neonatal murine cardiomyocytes is
regulated by the actions of the VAChT. To test this hypothesis, we will
pharmacologically inhibit the VAChT in control mice using VES and we will also
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analyze a genetically modified mouse line in which this transporter has been
conditionally removed from cardiomyocytes.
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Chapter 2

2

Methods

2.1 Animals
Transgenic mice used for the present study were acquired from JAX Laboratories
(B6.FVB-Tg(Myh6-cre)2182Mds/J, stock #011038). Expression of Cre in these mice was
under the control of the cardiomyocyte-specific murine alpha myosin-heavy chain
promoter (Myh-6-cre). Once acquired, transgenic mice were then bred to VAChT-floxed
mice (VAChTflox/flox) (Guzman et al., 2011; Martins-Silva et al., 2011). All procedures
and animals used in this thesis were approved by the local animal users committee
(Protocol# 2008-127). As described previously, VAChTflox/flox mice were backcrossed 5
times to C57BL6/j mice (Guzman et al., 2011). Furthermore, it should be noted that
VAChTflox/flox mice were no different from wild-type mice (Martins-Silva et al., 2011). In
order

to

generate

VAChTflox/flox,Myh6-Cre+

and

VAChTflox/flox,Myh6-Cre-

mice,

VAChTWT/flox,Myh6-Cre+ littermates were crossed with VAChTWT/flox,Myh6-Cre- littermates.
Mice used for the present study were generated by breeding F2 littermates together. For
the present study, VAChTflox/flox,Myh6-Cre- littermates were considered as controls.

2.2 Neonatal Cardiomyocyte Cultures
Neonatal cardiomyocytes were cultured as previously described (Guatimosim et al.,
2008) and used for all subsequent experiments. Neonatal cardiomyocytes were used over
their adult counterparts as adult cardiomyocytes are only viable in culture for a short
period of time consequently making them difficult to work with and obtain accurate
results. In short, neonatal mice were sterilized, decapitated, and their hearts were
extracted with any excess blood being removed by gently shaking the hearts in Hanks’
Balanced Salt Solution [(HBSS; Sigma Aldrich; 55021C) (5.37 mmol/L potassium
chloride, 0.44 mmol/L potassium phosphate monobasic anhydrous, 4.17 mmol/L sodium
bicarbonate, 136.89 mmol/L sodium chloride, 0.336 mmol/L sodium phosphate dibasic
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heptahydrate, 5.55 mmol/L dextrose anhydrous, and 0.028 mmol/L phenol red sodium
salt)]. Hearts were then cut, washed, and supplemented with 2 mL of Liberase solution
[Liberase TH enzyme (Roche; 05401135001) stock solution reconstituted in 10 mL of
HBSS] before being left in a water bath at 37oC with agitation for 10 minutes. The tissue
was replaced with 4 mL of fresh Liberase solution and incubated at 37oC for 15 minutes.
Cardiomyocytes were suspended in the Liberase solution and centrifuged at 200 x g for 5
minutes at 23oC. The supernatant was discarded and the pellet was re-suspended in 3 mL
of complete M199 medium (Sigma M4530) supplemented with 100 units/mL penicillin,
100 μg/mL streptomycin, 10% Fetal Bovine Serum and 2 mmol/L L-glutamine. The
process was repeated with the remaining undigested tissue before the cardiomyocytes
were pre-plated in a petri dish (diameter x height: 100 mm x 25 mm) and incubated in a
37oC incubator with 5% CO2 for 90 minutes. Following incubation, any tissue residue
present at the surface of the medium was removed before the cardiomyocytes were resuspended. The resulting medium was centrifuged using the same parameters as
previously described and the supernatant was discarded with the pellet being resuspended in complete M199 medium. In the case of assay-based studies,
cardiomyocytes were re-suspended in enough medium such that each well of a 4 well
plate contained 3 x 105 cells. In the case of microscopy-based studies, cardiomyocytes
were re-suspended in enough medium such that each plate contained 1.5 x 105 cells.
Cardiomyocytes used for assay-based studies were left to incubate overnight while
cardiomyocytes used for microscopy-based studies were left in the incubator for 30
minutes before additional medium was added. These plates were then placed in the
incubator for overnight incubation. The following morning, cardiomyocytes were
examined and the medium was changed to complete M199 medium supplemented with
20 μg/mL of cytosine-D-arabinofuranoside (ARA-c) (Sigma Aldrich; C1768). Following
incubation with ARA-c for 48 hours, the medium was changed to warmed M199
medium. Cardiomyocytes were then used for their respective experiments (ie.
Immunofluorescence/confocal microscopy, DAF-FM Diacetate Imaging, HPLC-ED, or
the Choline/ACh Fluorometric Assay). Cardiomyocytes to be used for these experiments
could be left in a 37oC incubator with 5% CO2 for up to one week from the initial culture
day before they were no longer viable.
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2.3 Genotyping
Tail snips were taken from1-2 day old neonatal mice, placed in Eppendorf tubes, and
supplemented with 25 µL of extraction solution (Sigma Aldrich; E7526) and 7 µL of
tissue preparation solution (Sigma Aldrich; T3073). Eppendorf tubes were placed in a
water bath at 37oC for 10 minutes with agitation and then placed onto a hot plate at 95oC
for 5 minutes. Eppendorf tubes were supplemented with 25 µL of neutralization buffer
(Sigma Aldrich; N9310) and vortexed before each neutralized solution was added to a
PCR tube containing REDExtract-N-AMP PCR Reaction Mix (Sigma Aldrich; R4775)
and primers (Flox GF, Flox GR, Cre-1, Cre-2, and VAT2DET2S). The positive control
was supplemented with 1.5 µL of solution from a tube containing a tail snip of a Myh-6Cre Fx2 mouse. PCR tubes were then vortexed and spun down before being run on a PCR
machine using a pre-made program. Upon completion of the program, each well of a 2%
agarose gel was loaded with 7 µL of the resulting solution from its corresponding PCR
tube. A 1 kb DNA ladder was also loaded for reference. The agarose gel was then run on
a GE Gel Electrophoresis machine at 120 mv for 40 minutes and imaged.

2.4 Cell Fixation and Immunofluorescence
1-2 day old neonatal cardiomyocytes were cultured as previously described. Following a
48 hour treatment with 20 μg/mL of ARA-c, medium present on cell culture plates was
aspirated and cardiomyocytes were washed 3x using 1x Phosphate Buffer Solution
(PBS). Cardiomyocytes were then covered with 4% paraformaldehyde (PFA), protected
from light, and allowed to fix before being blocked with blocking solution (1x PBS +
1%BSA + 0.5% Triton X-100). Cardiomyocytes were then incubated with anti-VAChT
(Synaptic Systems) and α-Actinin (Sigma Aldrich) antibodies diluted 1:50 in blocking
solution. Plates containing the anti-VAChT and α-Actinin antibodies were incubated
overnight at 4oC. The following morning, cardiomyocytes were washed as previously
described and incubated with secondary antibodies (Goat-α-Rabbit 488 and α-mouse 546)
diluted 1:1000 in blocking solution. Each plate was left covered at room temperature for
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1 hour before cardiomyocytes were subjected to nuclear staining using Hoescht
Fluorescent Stain. Finally, cardiomyocytes were left in 2 mL of PBS, placed in a wet
chamber, and left at 4oC until they were to be imaged. Imaging was completed using the
63x objective lens of a Zeiss LSM 510 Meta confocal system.

2.5 DAF-FM Fluorescence
1-2 day old neonatal cardiomyocytes were cultured as previously described. Following a
48 hour treatment with 20 μg/mL of ARA-c, the medium was removed, and
cardiomyocytes were washed using 1mL of tyrode (140 mmol/L NaCl, 4 mmol/L KCL, 1
mmol/L MgCl2, 1.8 mmol/L CaCl2, 10 mmol/L Glucose, and 5 mmol/L HEPES). Tyrode
was then removed and replaced with 250 µL of DAF-FM (Invitrogen; D-23842) diluted
in tyrode at a final concentration of 5 µM for 30 minutes. DAF-FM in tyrode was
removed and cardiomyocytes were washed with 250 µL of fresh tyrode for 30 minutes.
Cardiomyocytes were then either imaged (controls) or treated with various drugs
including Pyridostigmine (100 µM) (Sigma Aldrich; P9797), Carbachol (10 µM) (Sigma
Aldrich; C2409), Atropine (10 µM) (Sigma Aldrich; A0132), Hemicholinium-3 (10 µM)
(Sigma Aldrich; H108) or Vesamicol (10 µM) (Sigma Aldrich; V100) for 30 minutes and
then imaged. For the positive control, 1 nM sodium nitroprusside (SNP), a known nitric
oxide (NO) donor, was added to a plate for approximately 1 minute and then imaged to
determine if the assay was functioning properly. Images from each treatment were
acquired using the 63x objective lens of a Leica SP5 II confocal system. Images were
then analyzed using ImageJ software.

2.6 Choline/ACh Fluorometric Assay
Cardiomyocytes were cultured from VAChTflox/flox and VAChTMyh6-Cre-flox/flox neonatal
mice as previously described. Following a 48 hour treatment with 20 μg/mL of ARA-c,
VAChTflox/flox and VAChTMyh-6-Cre-flox/flox cardiomyocytes were treated with either
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pyridostigmine (100 µM) or pyridostigmine and vesamicol (10 µM). The cultured
medium was then collected, centrifuged at 13,200 RPM for 5 minutes at 4oC, and filtered
using a 0.2 µM Acrodisc Syringe Filter (PALL Life Sciences; PN=4602). Known
concentrations of ACh (0, 10, 20, 30, 40, and 50 pmol/well), as well as filtered cultured
medium samples, were added to a 96-well plate and the volumes were adjusted to 50
µL/well using choline assay buffer (Biovision; K615-100-1). Next, two separate reaction
mixes were created. The first reaction mix was created such that 50 µL of mix could be
added to each well in the following proportions: 44 µL choline assay buffer, 2 µL choline
probe (Biovision; K615-100-2A), 2 µL AChE (Biovision; K615-100-2), and 2 µL
enzyme mix (Biovision; K615-100-4). The second reaction mix was created in a similar
fashion with the exception of AChE. Instead, the second mix was created such that the
AChE was replaced with an equivalent volume of choline assay buffer. Once the reaction
mixes were added to their respective wells, the 96-well plate was removed from ice,
covered with aluminum foil, and left at room temperature for 30 minutes. The 96-well
plate was then placed into a micro-plate reader with an Ex/Em=535/590 and a readout
with given values was produced. The results were then normalized by subtracting the
blank (ie. the 0 pmol/well standard) value from those values obtained for each well
containing either a known standard or cultured medium. To determine the amount of ACh
present within the cultured medium, the normalized values from wells lacking AChE (ie.
free choline) were subtracted from the normalized values of wells containing AChE (ie.
total choline). These values were then applied to a standard curve generated using known
ACh standards.

2.7 HPLC-Electrochemical Detection (HPLC-ED)
Cardiomyocytes from VAChTflox/flox and VAChTMyh6-Cre-flox/flox neonatal mice were
cultured as previously described. Following a 48 hour treatment with 20 μg/mL of ARAc, cardiomyocytes were treated with either pyridostigmine (100 µM) or pyridostigmine
and vesamicol (10 µM) and left to incubate for 4 hours in a 37oC incubator with 5% CO2.
Following incubation, the cultured medium was collected, centrifuged at 13,200 RPM for
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5 minutes at 4oC, and filtered using a 0.2 µM Acrodisc Syringe Filter. The filtered
cultured medium was loaded onto the autosampler of an UltiMATE 3000 HPLC system
with a Coulochem electrochemical detector (ED). The cultured medium was then injected
onto the UltiMATE 3000 system using the following components and parameters: Flow
rate: 0.300 mL/min; Injection volume: 20 µL; Cell: Model 5040 amperometric cell with
platinum target electrode (Thermo Scientific; 70-1074); Cell potential: 275 mV; Column:
MGII CAPCELL PAK C18 column (Shiseido; Cat. No.= 92461); Column temperature:
40oC; ACh post-column solid phase reactor (Thermo Scientific; 70-0640A)

2.8 Statistical Analysis
GraphPad Prism 6 was used for all statistical analysis in this study. The results for each
of the experiments are provided as mean ± SEM. A student’s t-test or a one-way ANOVA
with a Tukey’s post-hoc test were used to determine the statistical significance between
experimental groups. p<0.05 was considered to be statistically significant for all analyses.
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Chapter 3

3

Results

3.1 Neonatal Cardiomyocytes Secrete ACh in an Autocrine
or Paracrine Fashion
To determine if neonatal cardiomyocytes could secrete ACh, initially a DAF-FM
bioassay was utilized. In this assay, secreted ACh elicits an increase in NO production
and this production can be measured by DAF fluorescence. If neonatal cardiomyocytes
could secrete ACh, it would be interesting to determine whether or not neonatal
cardiomyocytes do so in an autocrine/paracrine fashion. Results obtained from the DAFFM bioassay would provide a foundation from which we could expand upon to better
understand the way in which the non-neuronal cholinergic system functions in neonatal
cardiomyocytes (Figure 1).
Here we show that when VAChTflox/flox neonatal cardiomyocytes were subjected to AChE
inhibition by PYR (100 µM), those cells exhibited a significant increase in DAF
fluorescence similar to that observed in cardiomyocytes treated with exogenous Carb (10
µM). The increase in DAF fluorescence following AChE inhibition signifies the
preservation of ACh release by neonatal cardiomyocytes. The effects of PYR, as well as
Carb, were blocked however, following pre-incubation with ATR (10 µM). To ensure the
assay was functioning properly, VAChTflox/flox neonatal cardiomyocytes were treated with
sodium nitroprusside (SNP), a known NO donor. Treatment with SNP resulted in a
significant increase in DAF fluorescence compared to cardiomyocytes treated with
exogenous Carb or PYR.
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Figure 1. Acetylcholine release from cultured neonatal cardiomyocytes was
determined using a DAF-FM bioassay following acute pharmacological treatments.
(A) Representative images obtained using confocal microscopy depicting increased DAF
fluorescence in VAChTflox/flox neonatal cardiomyocytes following acute treatment with 10
µM exogenous carbachol (Carb) or 100 µM pyridostigmine (PYR) and no change in
fluorescence when treated with 10 μM atropine (ATR), 10 μM ATR + 10 μM Carb, or 10
μM ATR + 100 μM PYR. (B) Normalized DAF fluorescence in 1-2 day old
VAChTflox/flox neonatal cardiomyocytes following acute treatment with exogenously
added Carb, PYR, ATR or SNP. Number of cells subjected to each treatment are shown
within their respective bars (n=). Cells were acquired from five separate neonatal
cardiomyocyte cultures. Scale bar=20 μm. ***p<0.0001. Data are shown as mean ±
SEM.
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3.2 Pharmacological Inhibition of CHT1 by Hemicholinium-3
Compromises
ACh
Release
from
Neonatal
Cardiomyocytes
The high affinity choline transporter, CHT1, has been shown to serve a critical role in
regulating the re-uptake of choline into presynaptic cholinergic neurons (Ferguson et al.,
2004). This is evident considering that a disruption in the CHT1 gene results in impaired
cholinergic neurotransmission (Ferguson et al., 2004). Interestingly, work by RochaResende et al., 2012 revealed the importance of CHT1 in the synthesis and subsequent
release of ACh by adult cardiomyocytes, as pharmacological inhibition of this transporter
by HEM severely compromised ACh release. Interestingly, Rana et al., 2010 were unable
to locate CHT1, as well as other cholinergic proteins, within neonatal rat cardiomyocytes.
Therefore, the purpose of this experiment was to determine, using DAF fluorescence,
whether or not CHT1 regulates choline re-uptake and the subsequent release of ACh from
neonatal murine cardiomyocytes (Figure 2). These data would not only provide evidence
supporting ACh release by neonatal cardiomyocytes but they would inform us on whether
or not a functional non-neuronal cholinergic system is present at birth and the possible
physiological implications that this may have on cardiac development. Furthermore, they
would provide greater insight into how a non-neuronal cholinergic system functions in
cardiomyocytes.
Following experimentation, we once again show that ACh release from VAChTflox/flox
neonatal cardiomyocytes is preserved following AChE inhibition. Interestingly however,
the effects of AChE inhibition were abolished when VAChTflox/flox neonatal
cardiomyocytes were pre-incubated with HEM (10 µM). Treatment with SNP resulted in
a significant increase in DAF fluorescence compared to those cardiomyocytes treated
with exogenous Carb, PYR, or HEM + Carb signifying that the assay was functioning
properly.
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Figure 2. Acetylcholine release from cultured neonatal cardiomyocytes was
determined using a DAF-FM bioassay following acute pharmacological treatments.
(A) Representative images obtained using confocal microscopy depicting increased
DAF fluorescence in VAChTflox/flox neonatal cardiomyocytes following treatment with
10 µM exogenous carbachol (Carb), 100 µM pyridostigmine (PYR), or 10 μM
hemicholinium-3 (HEM) + 10 μM Carb and no change in fluorescence when treated
with 10 μM HEM or 10 μM HEM + 100 μM PYR. (B) Normalized DAF fluorescence
in 1-2 day old VAChTflox/flox neonatal cardiomyocytes following acute treatment with
exogenously added Carb, PYR, HEM, or SNP. Number of cells subjected to each
treatment are shown within their respective bars (n=). Cells were acquired from six
separate neonatal cardiomyocyte cultures. Scale bar=20 μm. ***p<0.0001. Data are
shown as mean ± SEM.
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3.3 Pharmacological Inhibition of the Vesicular
Acetylcholine Transporter by Vesamicol Compromises
ACh Release from Neonatal Cardiomyocytes
Previously, it has been shown that the VAChT serves a critical role in mediating the
release of ACh from cholinergic neurons (de Castro et al., 2009), and it has yet to be fully
determined if this transporter serves a similar role within neonatal cardiomyocytes. To
elucidate whether or not the VAChT serves a similar physiological role in regulating the
release of ACh from neonatal cardiomyocytes, the transporter was pharmacologically
inhibited using vesamicol (VES) (Figure 3).
Here we further confirm those observations previously reported (Rocha-Resende et al.,
2012) that the release of ACh by VAChTflox/flox neonatal cardiomyocytes is preserved
following AChE inhibition. When VAChTflox/flox neonatal cardiomyocytes were preincubated with VES however, the release of ACh was inhibited despite the cells being
subjected to AChE inhibition. Treatment with SNP resulted in a significant increase in
DAF fluorescence compared to those cardiomyocytes treated with exogenous Carb, PYR,
or VES+Carb signifying that the assay was functioning properly.
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Figure 3. Acetylcholine release from cultured neonatal cardiomyocytes was
determined using a DAF-FM bioassay following acute pharmacological treatments.
(A) Representative images obtained using confocal microscopy depicting increased DAF
fluorescence in VAChTflox/flox neonatal cardiomyocytes following acute treatment with 10
µM exogenous carbachol (Carb), 100 µM pyridostigmine (PYR), or 10 μM vesamicol
(VES) + 10 μM Carb and no change in fluorescence when treated with 10 μM VES or 10
μM VES + 100 μM PYR. (B) Normalized DAF fluorescence in 1-2 day old VAChTflox/flox
neonatal cardiomyocytes following acute treatment with exogenously added Carb, PYR,
VES, or SNP. Number of cells subjected to each treatment are shown within their
respective bars (n=). Cells were acquired from six separate neonatal cardiomyocyte
cultures. Scale bar=20 μm. ***p<0.0001. Data are shown as mean ± SEM.
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3.4 The Conditional Removal of the Vesicular ACh
Transporter from Neonatal Cardiomyocytes
To further test for the role that the VAChT serves in mediating the release of ACh from
neonatal cardiomyocytes, the transporter was conditionally removed from these cells. To
differentiate VAChTflox/flox mice from VAChTMyh-6-Cre-flox/flox mice for subsequent
experimentation, each mouse from a given litter was genotyped as previously described.
Briefly, tail snips were taken from neonatal mice and subjected to PCR before the
resulting DNA was run on a 2% agarose gel. For reference, a representative gel (Figure
4) is shown to illustrate VAChTflox/flox and VAChTMyh-6-Cre-flox/flox genotyping. Each
numbered lane represents a lane corresponding to a given mouse. Lanes labeled “P” and
“N” are positive and negative controls, respectively. “L” represents a 1kb DNA ladder.
VAChTflox/flox and VAChTMyh-6-Cre-flox/flox genotypes were determined by the presence of
the flox/flox gene and either the absence or presence of Cre, respectively. In Figure 4,
lanes 7, 10-12, and 14 denote mice of the VAChTflox/flox genotype, whereas the remaining
lanes (1-6, 8, 9, and 13) denote mice of the VAChTMyh-6-Cre-flox/flox genotype. To confirm
that the VAChT had been conditionally removed from VAChTMyh-6-Cre-flox/flox
cardiomyocytes, immunostaining followed by confocal microscopy were performed on
both VAChTflox/flox (Figure 5a) and VAChTMyh-6-Cre-flox/flox (Figure 5b) neonatal
cardiomyocytes. Following the analysis of VAChTflox/flox neonatal cardiomyocytes,
immunostaining and confocal microscopy revealed the presence of the VAChT within the
perinuclear region. However, immunostaining and confocal microscopy in VAChTMyh-6Cre-flox/flox

neonatal cardiomyocytes revealed no such VAChT staining within the

perinuclear region. The lack of VAChT staining within these cardiomyocytes confirms
the selective removal of the VAChT from neonatal cardiomyocytes.
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Figure 4. Genotyping analysis of a cardiomyocyte specific VAChT KO mouse strain.
An agarose gel used to distinguish VAChTflox/flox and VAChTMyh-6-Cre-flox/flox genotypes
has been shown. Bands denoting Cre have been boxed in red while bands denoting flox
have been boxed in yellow. Lanes 1-6, 8, 9, & 13 denote floxed Cre+ mice (VAChTMyh-6Cre-flox/flox

), while lanes 7, 10-12, & 14 denote floxed Cre- mice (VAChTflox/flox). DNA

obtained via tail snip from VAChTMyh-6-Cre-flox/flox mice was used as a positive control
(Lane P) to show the presence of Cre. DNA obtained via tail snip from VAChTflox/flox
mice was used as a negative control (Lane N) to show the absence of Cre. Lane L is a 1kb
DNA ladder.
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Figure 5. Conditional removal of the VAChT from cardiomyocytes in VAChTMyh-6mice

Cre-flox/flox

Representative images obtained by immunostaining and confocal microscopy showing
the presence and absence of the VAChT within (A) VAChTflox/flox and (B) VAChTMyh-6Cre-flox/flox

µm.

neonatal cardiomyocytes, respectively. n=20 for both genotypes. Scale bar=20
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3.5 The Conditional Removal of the Vesicular ACh
Transporter from Neonatal Cardiomyocytes Severely
Compromises ACh Release
Previous work has shown that the VAChT is essential in regulating the release of ACh
from cholinergic neurons, as well as sustaining life, since deletion of this gene prevented
the stimulated release of ACh from synaptosomes and resulted in death of the animals
shortly after birth (de Castro et al., 2009). Furthermore, the essential role that the VAChT
serves in mediating the release of ACh from cholinergic neurons has been shown in
VAChT KDHOM mice. These mice exhibit alterations at the neuromuscular junction (de
Castro et al., 2009) and display a myasthenic-like phenotype (V. F. Prado et al., 2006).
To further determine if the VAChT serves a similar role within neonatal cardiomyocytes,
we compared ACh release between VAChTflox/flox and VAChTMyh-6-Cre-flox/flox genotypes.
Initially, VAChTflox/flox and VAChTMyh-6-Cre-flox/flox neonatal cardiomyocytes were
subjected to analysis using the DAF-FM experimental approach as previously described
(Figure 6). Here it was shown that the release of ACh by VAChTflox/flox neonatal
cardiomyocytes was preserved following AChE inhibition, but no such preservation was
observed in VAChTMyh-6-Cre-flox/flox neonatal cardiomyocytes subjected to the same
treatment.
To further test these findings, cultured medium was collected from VAChTflox/flox and
VAChTMyh-6-Cre-flox/flox neonatal cardiomyocytes treated with either PYR (100 µM) or
PYR + VES (10 µM) and subjected to analysis by a choline/ACh fluorometric assay
(Figure 7). Both VAChTflox/flox and VAChTMyh-6-Cre-flox/flox neonatal cardiomyocytes were
maintained in medium containing PYR to preserve ACh from degradation by AChEs. To
determine the amount of ACh released under each of these conditions, standard curves
were created separately for each assay using known ACh standards. One such standard
curve has been shown for representative purposes (Figure 7c). Analysis revealed that
VAChTflox/flox neonatal cardiomyocytes treated with VES released significantly less ACh
compared to control cardiomyocytes incubated with only PYR (PYR: 199.2 ± 17.65
pmols ACh/mg of protein, PYR+VES: 30.73 ± 3.89 pmols ACh/mg of protein, p<0.0001)
(Figure 7a).
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To further test these observations using genetic tools instead of pharmacology,
VAChTflox/flox and VAChTMyh-6-Cre-flox/flox neonatal cardiomyocytes were treated with PYR
(100 µM) before their cultured media were collected and subjected to fluorometric
analysis (Figure 7b). Through the use of standard curves, it was determined that there
was a significant reduction in ACh release from VAChTMyh-6-Cre-flox/flox neonatal
cardiomyocytes compared to VAChTflox/flox neonatal cardiomyocytes (VAChTflox/flox:
203.7 ± 23.95 pmols ACh/mg of protein, VAChTMyh-6-Cre-flox/flox: 1.67 ± 1.67 pmols
ACh/mg of protein, p<0.001).
To further confirm the lack of ACh release by VAChTMyh-6-Cre-flox/flox neonatal
cardiomyocytes, cultured media were collected from VAChTflox/flox and VAChTMyh-6-Creflox/flox

neonatal cardiomyocytes which were treated with either PYR (100 µM) or PYR +

VES (10 µM) and then subjected to analysis by HPLC-ED (Figure 8). To determine the
amount of ACh released under each of these conditions, standard curves were created
separately for each run using known ACh standards. One of these curves has been shown
for representative purposes (Figure 8e). Representative chromatograms for VAChTflox/flox
neonatal cardiomyocytes treated with either PYR or PYR + VES, along with a 500 fmol
on the column (OTC) standard, have been shown for comparison (Figure 8c). Following
the analysis of all runs from four separate neonatal cultures, the data revealed a
significant reduction in ACh release from VAChTflox/flox neonatal cardiomyocytes treated
with PYR+VES compared to those cardiomyocytes treated with only PYR (PYR: 37.76
± 4.51 pmols ACh/mg of protein, PYR+VES: 2.03 ± 1.17 pmols ACh/mg of protein,
p<0.0001) (Figure 8a).
To further compare VAChTflox/flox and VAChTMyh-6-Cre-flox/flox neonatal cardiomyocytes,
they were treated with PYR (100 µM) and subjected to the same analysis. Representative
chromatograms for VAChTflox/flox or VAChTMyh-6-Cre-flox/flox neonatal cardiomyocytes
treated with PYR, along with a 250 fmol OTC standard, have been shown for comparison
(Figure 8d). Analysis revealed a significant reduction in ACh release from VAChTMyh-6Cre-flox/flox

neonatal cardiomyocytes compared to VAChTflox/flox neonatal cardiomyocytes

(VAChTflox/flox: 47.89 ± 8.76 pmols ACh/mg of protein, VAChTMyh-6-Cre-flox/flox: 0.05 ±
0.03 pmols ACh/mg of protein, p<0.01) (Figure 8b).
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Figure 6. Acetylcholine release from cultured VAChTflox/flox and VAChTMyh-6-Creneonatal cardiomyocytes was determined using a DAF-FM bioassay following
acute pharmacological treatments.

flox/flox

(A) Representative images obtained using confocal microscopy for VAChTflox/flox and
VAChTMyh-6-Cre-flox/flox neonatal cardiomyocytes following acute treatment with either 10
μM carbachol (Carb) or 100 μM pyridostigmine (PYR). Acute treatment with 10 μM
Carb revealed a significant increase in DAF fluorescence in both VAChTflox/flox and
VAChTMyh-6-Cre-flox/flox neonatal cardiomyocytes, whereas treatment with 100 μM PYR
produced a significant increase in DAF fluorescence only in VAChTflox/flox neonatal
cardiomyocytes B. Normalized fluorescence for 1-2 day old VAChTflox/flox and
VAChTMyh-6-Cre-flox/flox neonatal cardiomyocytes following acute treatment with
exogenously added Carb or PYR. Number of cells subjected to each treatment are shown
within their respective bars (n=). Cells were acquired from six separate neonatal
cardiomyocyte cultures. Scale bar=20 μm.*p<0.05. Data are shown as mean ± SEM.
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Figure 7. Acetylcholine secreted by VAChTflox/flox and VAChTMyh-6-Cre-flox/flox
neonatal cardiomyocytes was measured using using a choline/ACh Fluorometric
Assay.
(A) Cultured VAChTflox/flox neonatal cardiomyocytes underwent acute treatment with
either 100 μM pyridostigmine (PYR) or 100 μM PYR + 10 μM vesamicol (VES).
Cultured media from a given treatment were separated from cells and the amount of
secreted ACh was quantified. n=number of separate neonatal cardiomyocyte cultures for
each treatment. ***p<0.0001 vs PYR. (B) Cultured VAChTflox/flox and VAChTMyh-6-Creflox/flox

neonatal cardiomyocytes underwent acute treatment with 100 μM PYR. Cultured

media from a given genotype were separated from cells and the amount of secreted ACh
was quantified. n=number of separate neonatal cardiomyocyte cultures for each genotype.
**p<0.001 vs CT. (C) Representative standard curve used for the measurement of ACh
created using a Choline/ACh fluorometric assay.
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Figure 8. Acetylcholine secreted by VAChTflox/flox and VAChTMyh-6-Cre-flox/flox
neonatal cardiomyocytes was measured using HPLC with electrochemical detection
(ED).
(A) Cultured VAChTflox/flox neonatal cardiomyocytes underwent acute treatment with
either 100 μM pyridostigmine (PYR) or 100 μM PYR + 10 μM vesamicol (VES).
Cultured media from a given treatment were separated from cells and the amount of
secreted ACh was quantified. n=number of separate neonatal cardiomyocyte cultures for
each treatment. ***p<0.001 vs PYR (B) Cultured VAChTflox/flox and VAChTMyh-6-Creflox/flox

neonatal cardiomyocytes underwent acute treatment with 100 μM PYR. Cultured

media from a given genotype were separated from cells and the amount of secreted ACh
was quantified. n=number of separate neonatal cardiomyocyte cultures for each genotype.
**p<0.01 vs VAChTflox/flox. (C) Representative chromatograms showing ACh release
from VAChTflox/flox neonatal cardiomyocytes following treatment with either 100 μM
PYR or 10 μM VES + 100 μM PYR, along with a blank and 250 fmol OTC standard for
comparison. Numbers present above each peak represent retention times.

(D)

Representative chromatograms showing ACh release from VAChTflox/flox and VAChTMyh6-Cre-flox/flox

neonatal cardiomyocytes following treatment with 100 µM PYR, along with a

blank and 500 fmol OTC standard for comparison. Numbers present above each peak
represent retention times. (E) A representative standard curve ranging from 125-1000
fmols OTC used to quantify ACh release.
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Chapter 4

4

Discussion

4.1 Overview
The recent emergence of non-neuronal cholinergic systems within biological systems
such as the pancreas, the placenta, and the colon has provided insight and understanding
into both the physiology, as well as the pathophysiology, associated with these systems.
Recently, it has been reported that the heart possess an intrinsic non-neuronal cholinergic
system, as the machinery required to synthesize and release ACh is present within
cardiomyocytes themselves (Kakinuma et al., 2009; Rana et al., 2010; Rocha-Resende et
al., 2012). However, there are controversial results regarding whether or not neonatal
cardiomyocytes also possess this machinery as a recent report was unable to show the
presence of cholinergic machinery in neonatal cardiomyocytes (Rana et al., 2010). In
order to investigate the mechanisms involved in regulating ACh release from neonatal
cardiomyocytes, a mouse line in which the VAChT has been conditionally removed has
been generated. By utilizing a DAF-FM bioassay, a choline/ACh fluorometric assay, and
HPLC-ED, we have shown pharmacologically, as well as genetically, that neonatal
cardiomyocytes secrete ACh in a VAChT-dependent manner. The results obtained from
neonatal cardiomyocytes agree with previous observations by Rocha-Resende et al., 2012
that isolated adult cardiomyocytes can secrete ACh and can act in an autocrine/paracrine
fashion through mAChRs-2. Furthermore, our results provide support for the role of
CHT1 in the synthesis and subsequent release of ACh from adult cardiomyocytes
(Rocha-Resende et al., 2012). These results also indicate that the non-neuronal
cholinergic system is not only present in adult cardiomyocytes, but that it’s also present
during the maturation of cardiomyocytes as well. The most important finding however,
as previously mentioned, was determining how essential the role of the VAChT is in
regulating ACh release from neonatal cardiomyocytes.
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4.2 ACh Release from Cardiomyocytes can Act in an
Autocrine or Paracrine Fashion to Further Stimulate the
Production of ACh
The DAF-FM bioassay works based on the principle that secreted ACh elicits an increase
in NO production. This production can then be measured through the use of DAF
fluorescence. A study analyzing the non-neuronal cholinergic machinery within isolated
adult cardiomyocytes utilized the DAF-FM bioassay to show the secretion of ACh by
these cells (Rocha-Resende et al., 2012). It was also reported that non-neuronal ACh
secreted from isolated adult cardiomyocytes could act as a local signaling molecule
through the activation of mAChRs-2 (Rocha-Resende et al., 2012). The secretion of nonneuronal ACh by cardiomyocytes in an autocrine/paracrine fashion is of particular
importance as it may serve to be cardioprotective in nature through the amplification of
neuronally released ACh. By implementing a similar pharmacological approach on
cultured VAChTflox/flox neonatal cardiomyocytes, in conjunction with the DAF-FM
bioassay, we have been able to corroborate the findings by Rocha-Resende et al., 2012.
Our findings reveal that the effects of preserved ACh release from VAChTflox/flox neonatal
cardiomyocytes are blocked following treatment with ATR, a muscarinic receptor
antagonist, suggesting that non-neuronal ACh secreted by these cells acts in an
autocrine/paracrine fashion through mAChRs-2. Similar to those observations presented
by Rocha-Resende et al., 2012, our data also provide support to those findings presented
by Kakinuma et al., 2009. In this particular study, rat cardiomyocytes underwent
pharmacological treatment with 1 mM Pilocarpine, a non-selective muscarinic agonist, 1
μM of the cholinesterase inhibitor Donepezil, or 1 mM ATR. Following treatment with 1
mM Pilocarpine or 1 μM Donepezil, Kakinuma and colleagues observed a significant
increase in intracellular ACh content (Kakinuma et al., 2009). Conversely, pre-incubation
with 1 mM ATR prevented any significant increase in intracellular ACh and in fact,
produced a significant reduction in intracellular ACh (Kakinuma et al., 2009). These
observations suggest that ACh is synthesized and secreted constitutively by rat
cardiomyocytes and acts through mAChRs-2 to actuate ACh production. The amount of
ACh present within rat cardiomyocytes either increases or decreases from basal levels
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following mAChR-2 activation or inhibition, respectively. These findings suggest that
ACh produced by rat cardiomyocytes for subsequent release is in some way mediated by
the mAChR-2. Although not fully known, our findings could suggest a similar regulatory
role for the mAChR-2 in murine cardiomyocytes as well.
The ability for non-neuronal ACh to act in an autocrine/paracrine fashion through
muscarinic receptors is essential in maintaining normal physiology within several
biological systems such as the pancreas (Rodriguez-Diaz et al., 2011). In the pancreas for
instance, non-neuronal ACh secreted locally by the pancreatic alpha cells activates
muscarinic type-3 ACh receptors (mAChR-3) to maintain glucose homeostasis, as well as
proper insulin secretion. When the mAChR-3 is inhibited by J-104129, large fluctuations
in plasma glucose concentrations ensue as a consequence of consistently reduced insulin
responses (Rodriguez-Diaz et al., 2011).
In fact, the importance of non-neuronal ACh acting in an autocrine/paracrine fashion
through muscarinic receptors has been shown recently in the cardiovascular system as
well. It was reported that effectively abolishing the release of cardiomyocyte-derived
ACh from murine cardiomyocytes through either pharmacological or genetic means,
results in cardiomyocyte hypertrophy and cardiomyocyte remodeling (A. Roy et al.,
2013). Moreover, when subjected to stress, these mice presented with altered cardiac
contractility, as well as left ventricular function (A. Roy et al., 2013). These observations
suggest that the release of cardiomyocyte-derived ACh and its ability to activate
mAChRs-2 in an autocrine/paracrine fashion, is essential in maintaining cardiovascular
homeostasis since inhibiting this release through either pharmacological or genetic means
produces severe alterations in cardiomyocyte structure and function.
Taken together it becomes clear that several cells types, despite being non-neuronal in
nature, can secrete ACh and do so in an autocrine/paracrine fashion through mAChR.
More importantly, these data show that murine cardiomyocytes can secrete ACh in a
similar fashion and can activate mAChRs-2 to ensure cardiovascular homeostasis, by
maintaining cardiomyocyte structure and function.
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4.3 ACh Release from Cardiomyocytes is Compromised
Following Inhibition of CHT1 by Hemicholinium-3
As reported previously, the high affinity choline transporter, CHT1, is a protein essential
to cholinergic neurotransmission, as it mediates the synthesis of ACh by providing
cholinergic neurons with choline (Collier & Katz, 1974; R. Birks, 1961). This is evident
considering that mutant mice possessing a disruption in the CHT1 gene produced
alterations at the neuromuscular junction (Ferguson et al., 2004). Interestingly, these
alterations paralleled those exhibited by ChAT mutant mice incapable of synthesizing
ACh (Brandon et al., 2003; Misgeld et al., 2002) or VAChT mutants (de Castro et al.,
2009), suggesting that when CHT1 activity is compromised, the production and release of
ACh are also compromised. In the present study, CHT1 was pharmacologically inhibited
in cultured VAChTflox/flox neonatal cardiomyocytes using HEM. By pharmacologically
inhibiting this transporter, we could determine if CHT1 regulates choline re-uptake in
neonatal cardiomyocytes in a similar manner to neuronally-derived CHT1. Furthermore,
by pharmacologically inhibiting CHT1 in neonatal cardiomyocytes, we could determine
whether or not a non-neuronal cholinergic system is present and active during
development.
These data show that ACh secreted by VAChTflox/flox neonatal cardiomyocytes is
abolished, despite AChE inhibition, following pre-incubation with HEM. These data
provide support to those observations reported by Rocha-Resende et al., 2012 where they
pharmacologically inhibited CHT1 in isolated adult cardiomyocytes. Similar to the
observations we report, Rocha-Resende et al., 2012 reported that ACh secreted from
isolated adult cardiomyocytes was abolished following pre-incubation with HEM.
Considering

both

VAChTflox/flox

neonatal

cardiomyocytes

and

isolated

adult

cardiomyocytes are able to preserve ACh release following AChE inhibition, but fail to
do so following pre-incubation with HEM, suggests that the synthesis and subsequent
release of ACh by murine cardiomyocytes is highly dependent upon CHT1 activity and
its ability to regulate choline re-uptake. These data are important as they suggest that the
role of CHT1 in cardiomyocytes is similar to its role in cholinergic neurons. Taken
together, it becomes clearly evident that CHT1 is not only essential in regulating the re-
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uptake of choline in cholinergic neurons, but it also serves a critical role in maintaining
cholinergic tone within non-neuronal cell types as well.
The ability for CHT1 to regulate choline re-uptake not only in isolated adult
cardiomyocytes, but in neonatal cardiomyocytes as well, suggests that an intrinsic nonneuronal cholinergic system is active in cardiomyocytes during development. It is likely
that a non-neuronal cholinergic system is present in neonatal murine cardiomyocytes
where it serves, like adult cardiomyocytes (A. Roy et al., 2013), to prevent
cardiomyocyte remodeling and cardiomyocyte hypertrophy, as well as the functional
implications associated with these molecular changes.
Not only do our data show the importance of CHT1 in regulating the re-uptake of choline
by neonatal cardiomyocytes and the possible cardioprotective role it serves in the nonneuronal cholinergic system of cardiomyocytes, but they also suggest that these cells
require extracellular sources of choline to properly synthesize ACh. This becomes
important from a cholinergic signaling perspective as it has been previously reported that
the de novo synthesis of ACh by cholinergic neurons is negligible and nearly all choline
required for the synthesis of ACh must be acquired through dietary means (Fernstrom,
1981; Zeisel, 1981).

4.4 ACh Release from Cardiomyocytes is Regulated by the
Vesicular ACh Transporter
The role the VAChT serves within cholinergic neurotransmission has been well
documented previously (Parsons et al., 1993; Usdin et al., 1995). The role it serves in
packaging ACh into acidic vesicles is essential for sustaining life considering that
VAChT KOHOM mice are not viable shortly after birth (de Castro et al., 2009). In the
present study, we both confirm and extend those data describing the role of the VAChT
within cardiomyocytes by pharmacologically inhibiting the transporter, as well as
conditionally removing it, from neonatal cardiomyocytes.
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To more thoroughly understand the role this transporter serves in regulating ACh release
from neonatal cardiomyocytes, multiple studies involving the pharmacological inhibition
or conditional removal of the VAChT were performed. Experiments implementing the
DAF-FM bioassay indicate that the release of ACh by VAChTflox/flox neonatal
cardiomyocytes is compromised following treatment with VES. These findings are
consistent with DAF-FM data acquired from isolated ventricular cardiomyocytes of mice
with significant reductions in functioning VAChT protein (VAChT KDHOM), where it
was reported that ACh release was severely compromised despite AChE inhibition
(Rocha-Resende et al., 2012). Considering that AChEIs rely highly on preserved ACh
release to properly exert their functions, the inability for PYR or NEO to mediate an
increase in NO production (i.e. DAF fluorescence) when VAChT expression was
reduced, or when the transporter was pharmacologically inhibited, indicates that the
release of ACh was effectively abolished This becomes even more evident considering
that in both studies there was a significant increase in NO production when
cardiomyocytes were treated with either exogenous Carb or ACh. Moreover, DAF-FM
data acquired from VAChTMyh-6-Cre-flox/flox neonatal cardiomyocytes revealed no
significant increase in NO production following AChE inhibition indicating that the
VAChT is absolutely essential for the release of ACh by neonatal cardiomyocytes. These
observations indicate that ACh released by cardiomyocytes is completed in a VAChTdependent manner similar to the manner in which ACh is released from cholinergic nerve
terminals. This becomes evident considering that cardiomyocytes possess the recycling
vesicles necessary for VAChT-dependent ACh release (Rocha-Resende et al., 2012).
Interestingly, these vesicles have been shown to co-localize extensively with the VAChT
in the perinuclear region of cardiomyocytes (Rocha-Resende et al., 2012).
To further exam whether the release of ACh from cardiomyocytes occurs in a VAChTdependent manner, we utilized a choline/ACh fluorometric assay, as well as HPLC-ED,
on both VAChTflox/flox and VAChTMyh-6-Cre-flox/flox neonatal cardiomyocytes. Both methods
revealed results similar to those obtained following the pharmacological inhibition of the
VAChT. These data not only support our previous findings, but they extend both our
data, as well as the data of others, since until now no other study has shown through
direct measurement, the secretion of ACh by cardiomyocytes. Even more convincing
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however, is the fact that ACh release was almost completely undetectable by these
methods when VAChTMyh-6-Cre-flox/flox neonatal cardiomyocytes were used. Considering
that ACh secreted from cholinergic neurons in both the central and peripheral nervous
systems is strongly correlated with the level of VAChT expression (V. F. Prado et al.,
2006), our data would seem to suggest that the level of VAChT expression within
cardiomyocytes directly affects the amount of ACh released from these cells. Therefore,
the release of ACh in a VAChT-dependent manner is not only a characteristic of
cholinergic neurons, but also seems to be the manner in which ACh is secreted by
cardiomyocytes. VAChT-dependent secretion of ACh by cardiomyocytes becomes even
more plausible if one considers that other non-neuronal cholinergic systems have been
shown to secrete ACh in this manner (Rodriguez-Diaz et al., 2011). In a study by
Rodriguez-Diaz et al., 2011, AChE inhibition was ineffective in maintaining the
pancreas’ insulin response when the VAChT was pharmacologically inhibited by VES.
Taken together, both the pharmacological inhibition and conditional removal of the
VAChT severely compromised the release of ACh from cardiomyocytes. Moreover, there
were similar reductions in ACh release following both approaches. As it has been well
established that the VAChT is essential in mediating the release of ACh from cholinergic
neurons, results obtained following the pharmacological inhibition and conditional
removal of it would suggest a similar VAChT-dependent release by neonatal
cardiomyocytes. Determining the mechanism by which ACh is secreted by neonatal
cardiomyocytes allows for a better understanding of the intrinsic non-neuronal
cholinergic system within cardiomyocytes.

4.5 Conclusions and Future Directions
These data indicate that neonatal murine cardiomyocytes possess an intrinsic nonneuronal cholinergic system that can synthesize and subsequently release ACh in an
autocrine/paracrine fashion. Furthermore, pharmacologically inhibiting the VAChT or
conditionally removing it from neonatal cardiomyocytes severely compromised ACh
secretion suggesting that this process is VAChT-dependent. Although ACh release from
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neonatal cardiomyocytes is VAChT-dependent, it is yet to be determined how this release
changes under various physiological conditions such as acute and chronic stress.
Determining how these conditions affect ACh release is not only critical to understanding
cardiac physiology but it would also be critical to understanding the progression of
several cardiac pathologies including CHF. Additionally, understanding how ACh release
is altered under various physiological conditions may provide further insight into whether
or not an intrinsic non-neuronal cholinergic system is cardioprotective in nature.
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In the above publication, several contributions were made to see to its completion. My
contributions to the paper involved both the direct, as well as the indirect measurements
of ACh. More specifically, I was responsible for determining the amount of ACh released
from both VAChTflox/flox and VAChTMyh-6-Cre-flox/flox neonatal cardiomyocytes under
various pharmacological treatments using HPLC-ED and a choline/ACh fluorometric
assay. Additionally, I was responsible for all the data acquired from VAChTflox/flox and
VAChTMyh-6-Cre-flox/flox neonatal cardiomyocytes subjected to DAF-FM analysis.
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